retained throughout the duration of the study. Details of cell culture methods were described 1 4 3 previously [26] [27] [28] . Briefly, D283 Med and Daoy cells were grown in a humidified incubator at 1 4 4 37 0 C and 5% CO 2 atmosphere in growth media containing minimum essential media (MEM) 1 4 5 with Earle's Balanced Salt Solution (EBSS). Growth media for PFSK1 cells was RPMI 1640. growth and expansion, D283 Med cells were maintained in suspension culture at 0.5 -1 x 10 6 1 4 9 8 cells/ml. Daoy and PFSK1 cells were maintained between 20 and 80% confluence. Growth 1 5 0 media was refreshed every 2-3 days with cells split at a ratio of 1:5. Viability was assessed by accumulation of formazan by reduction 3-(4,5-dimethylthiazol-1 6 5 2-yl)-2,5-diphenyltetrazolium bromide (MTT) or 3-(4,5-dimethylthiazol-2-yl)-5-(3- Cultures were incubated at 37⁰C in 5% CO 2 overnight (18-24 hours) at which time cells were 1 7 6
exposed to the desired final concentration of cisplatin and incubated an additional 48 hours prior assay. free media, and then cultured in 2.5 mL of growth media at 37⁰C in 5% CO 2 until visible 1 9 0 colonies containing >50 cells were observed. Preliminary range finding concentration response 1 9 1 analysis was performed with each chemotherapeutic agent for each cell line, at the 1 9 2 concentrations used between 5-40 clones per plate were typically observe for vehicle cultures. Incubation times were typically between 2-3 weeks with growth media refreshed every 2-3 days.
1 9 4
Colonies were fixed and stained with 1% methylene blue in 50% ethanol (Fisher Scientific, images were captured and colonies were counted using an Alpha Innotech FluorChem FC2 Caspase Activity 2 0 0
All methods were done as previously described with D283 Med cells seeded into 96 well 2 0 1 plates at a density of 1 x 10 6 cells/ml in phenol red free MEM/EBSS lacking L-glutamine, 10% seeding with 20 mM Tris-HCl (pH 7.5) with 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1% 2 0 5
Triton. Cell lysates were assayed for protein concentration using the BioRad Dc protein assay percentage of the maximal inhibitory effect of 10 nM E2. GraphPad Prism v6 software (GraphPad Software, Inc., La Jolla, CA). Compared to vehicle treated D283 Med cells, the cytotoxic effects of cisplatin were 2 2 0 decreased in the presence of 10 nM E2 ( Fig. 1A-B ). When analyzed by an MTS reduction assay 2 2 1 the presence of E2 increased the observed IC 50 of cisplatin from 5.6 μM (95% CI 4.7 -6.9) to 2 2 2 14.7 μM (95% CI 10.5 -20.5; Fig. 1A ). Two-way ANOVA revealed a significant effect of Following the initial characterization studies of the effects of E2 on D283 Med cells in 2 3 4 viability assays, a clonogenic colony forming assay [38, 39] in which cytotoxic treatments 2 3 5
reproducibly caused 99-99.5% loss of viability was used to better determine the effects of 2 3 6 estrogens effects on the cytotoxicity of cisplatin. Based on preliminary concentration response 2 3 7 analysis (Fig. 1C) , the effect of 10 nM E2 on chemosensitivity of D283 Med cells to increasing 2 3 8 cisplatin concentrations (2, 4, or 9 μM) was characterized ( Fig. 1D-E) . At each cisplatin Med cells was independent of the cytotoxic mechanism of action, additional experiments were 2 4 2 performed to test the impact of E2 on lomustine and vincristine cytotoxicity (Fig. 2) . Initial for lomustine of 12.1 μM (95% CI 11.7 -12.6) ( Fig. 2A ) and 1.5 nM (95% CI 0.74 -3.1) for 2 4 5 vincristine (Fig. 2B) . The presence of E2 significantly protected D283 Med cells from the The use of aggressive multimodal treatments has resulted in increased survival for MB these drugs works in different ways to stop the growth of tumor cells, either by killing the cells, multiple cytotoxic treatments arising because each targets different processes involved in tumor 3 1 0 cell survival [45, 46] . Targeted cancer therapies based on molecular markers such as endocrine 3 1 1 therapy for prostate cancer or inhibiting ER activity in ER-positive breast cancer also benefits 3 1 2 from a multimodal treatment approach that can includes endocrine based therapies, along with 3 1 3 chemotherapy involving single or multiple cytotoxic agents [19, 20, [47] [48] [49] [50] [51] . Because E2 3 1 4 increases MB tumor survival through a general cytoprotective mechanism by increasing IGF-3 1 5 signaling [27], we hypothesized that its cytoprotective effects would decrease the cytotoxic 3 1 6 effects of chemotherapeutic agents used for MB treatment independent of their mechanism of 3 1 7
action. The presented studies, focused primarily on the most commonly used MB chemotherapy 3 1 8 drug cisplatin (a DNA crosslinking agent), found that estrogen and soy-derived phytoestrogens 3 1 9
were modestly cytoprotective, typically causing about a 2 fold increase in viability. The were also decreased by E2 in D283 Med MB cells demonstrating that the estrogen-induced cytoprotective mechanisms were in fact independent of the mechanism by which these 3 2 3
chemotherapeutic agents act to initiate MB cell death.
2 4
We and others have found that Daoy cells express ERβ, but the pattern of ERβ protein 3 2 5
isoform expression is distinctive from other MB and CNS-PNET cells in which E2 has 3 2 6
cytoprotective activities [26, 52] . We also previously found that estrogen stimulated the 3 2 7 migration of Daoy cells by an ERβ-dependent mechanism that was identical to that observed in 3 2 8
other MB and CNS-PNET cells [26] . It was found here however, that unlike other MB cells, E2 3 2 9
alone did not increase viability of Daoy cells, instead the presence of E2 increased sensitivity of 3 3 0 these cells to cisplatin cytotoxicity. It was also observed that inhibition of estrogen activity with 3 3 1 10 nM fulvestrant (a concentration that is 10-fold more than required to fully inhibit estrogen fulvestrant agonist activity on rapid estrogen signaling in MB remains to be clearly defined. is especially notable that the hypertetraploid karyotype of the Daoy cells does not resemble MB Quantification of surviving colony numbers from clonogenic assays of Daoy cells exposed to 2, 
